Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Print article
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Print article
PHS Technologies

Channels

Radiography

view channel

Surge in CT Scans for Patients with Minor Injuries

A new study reveals that almost twice as many patients with non-serious injuries are undergoing computerized tomography (CT) scans in the emergency department (ED) compared to a decade ago. Researchers at the University of California, San Francisco (UCSF; USA) and Stanford University (CA, USA) conducted a retrospective... Read more

Ultrasound

view channel
Image: The Verathon BladderScan Prime (Photo courtesy of Verathon).

Portable Ultrasound Device Quantifies Bladder Volume

A new portable three-dimensional (3D) ultrasound instrument helps reduce catheter-associated urinary tract infections (CAUTI) by reducing the use of catheters. The Verathon BladderScan Prime is a noninvasive... Read more

Nuclear medicine

view channel
Image: The SiPM detector (Photo courtesy of Volkmar Schultz, Aachen University).

New Hybrid PET/MRI System Developed for Enhanced Breast Cancer Imaging

A novel imaging technique is being developed that can improve breast cancer detection and characterization, and help clinicians evaluate the response of the cancer to treatment. The 4-year project,... Read more

General/Advanced Imaging

view channel

Healthcare IT Manufacturer and Teleradiology Interoperability Expert Introduce New FHIR System

A new interoperability system that was launched at the 2015 Radiological Society of North America (RSNA) annual meeting in Chicago, USA, in November, 2015, is now being introduced into the market. The system enables seamless integration of third party enterprise imaging systems using the latest Fast Healthcare Interoperability... Read more

Imaging IT

view channel
Image: Photo of the virtual reality device mobile diagnostic imaging (Photo courtesy of RSNA).

Prototype of Virtual Reality Device with Potential for Diagnostic Imaging Presented

A prototype of a high-resolution mobile Virtual Reality (VR) diagnostic imaging device for radiologists was presented at the annual Radiological Society of North America (RSNA 2015) meeting in Chicago (IL, USA).... Read more

Industry News

view channel

Radiology Oncology Surgical Robot Devices Sector Could Reach USD 7.3 Billion by 2022

A new report has been published indicating that worldwide market for radiology oncology surgical robots market is growing mainly due to an aging world population, and the benefits the new technology can offer. Radiology oncology surgical robot technology provides opportunities to change cancer treatment methods, including... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.